Australian Regulator Explains How To Comply With Advertising Rules While Meeting Continuous Disclosure Obligations
Executive Summary
Companies should avoid focusing only on the positive qualities of a therapeutic good or omitting or downplaying the negative qualities such as possible side effects, according to new guidance on therapeutic goods advertising and Australian Securities Exchange announcements.
You may also be interested in...
New Zealand Seeks Funding Applications For Rare Disorder Drugs
Applications from drug companies should also include a commercial proposal, says Pharmac.
England’s NICE Considers Challenges In Assessing Cost Effectiveness Of Alzheimer’s Drugs
Health technology assessment institute NICE is scheduled to appraise Eisai/Biogen’s lecanemab and Eli Lilly’s donanemab next year.
UK Clinical Trials Showing Signs Of Recovery But Global Ranking Still Poor
While things are starting to look up for the commercial clinical trial ecosystem in the UK, more progress is needed to improve industry’s confidence in the country as a destination for research, especially revenue-generating Phase III trials.